← Eichor
Condition: Participants With Advanced Solid Tumor Malignancies Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Participants With Advanced Solid Tumor Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid T
Phase 1 · 11 location(s) · Qurgen Inc. · NCT06873659A Study of HS-20110 in Participants With Advanced Solid Tumors
Phase 1 · 8 location(s) · Hansoh BioMedical R&D Company · NCT06892379Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Phase 1 · 3 location(s) · Adlai Nortye Biopharma Co., Ltd. · NCT07252479A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 19 location(s) · Bristol-Myers Squibb · NCT07160725Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1 · 16 location(s) · Coherus Oncology, Inc. · NCT05635643A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants Wi
Phase 1/Phase 2 · 38 location(s) · Shanghai Allink Biotherapeutics Co., Ltd. · NCT06656390A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Phase 1 · 6 location(s) · Samsung Bioepis Co., Ltd. · NCT07524348A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Phase 1 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07142980Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor
Phase 2 · 84 location(s) · Merck Sharp & Dohme LLC · NCT04924075A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
Phase 1 · 1 location(s) · L & L Bio Co., Ltd., Ningbo, China · NCT05357651First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Phase 1/Phase 2 · 17 location(s) · Biohaven Therapeutics Ltd. · NCT06384807Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT03810339Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
EARLY_Phase 1 · 1 location(s) · Ruijin Hospital · NCT06577532A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Phase 1 · 13 location(s) · Kumquat Biosciences Inc. · NCT07207707BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 8 location(s) · Shionogi · NCT05101070Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Phase 1 · 6 location(s) · Merck Sharp & Dohme LLC · NCT07600749A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · 9 location(s) · PAQ Therapeutics, Inc. · NCT07300150A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1/Phase 2 · 2 location(s) · Spago Nanomedical AB · NCT06184035A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma
Phase 2 · 35 location(s) · Day One Biopharmaceuticals, Inc. · NCT04775485A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130SKB105 for Injection in Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT07380386A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Phase 1 · 8 location(s) · Daiichi Sankyo · NCT05765851JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · OBI Pharma, Inc · NCT07124117Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.